Stocks · News reference

FDA Approves Merck's Belzutifan With Lenvatinib For Advanced Kidney Cancer With Clear Cell Component

Sep 24, 2026, 7:21 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 24, 2026, 5:53 PMTim Melvin
Alpha Buying: Follow the Money From NVIDIA and Merck
Wall Street loves a good upgrade, especially when the stock has already doubled and the analyst can explain why everyone should have owned it six months ago. One place I look for ideas is the investment portfolios of
ALEC COHR CRWV EIKN MRK
BenzingaSep 24, 2026, 5:40 PMVandana Singh
Merck Says Investigational Diabetes-Related Blindness Drug at Par With Roche’s Medicine
Merck reports Phase 2b/3 BRUNELLO trial data for remigromig in DME, achieving vision non-inferiority to ranibizumab alongside elevated adverse event rates.
MRK RHHBY
BenzingaSep 24, 2026, 10:48 AMBenzinga Newsdesk
Merck Says Topline Data From Phase 2b/3 BRUNELLO Trial Of Remigromig (MK-3000, Formerly EYE103) For Diabetic Macular Edema Met Its Primary Endpoint
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal Phase 2b/3 BRUNELLO trial in adults with diabetic macular edema (DME). BRUNELLO is the first of
MRK